Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial

Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now presents the RAPPORT study record for stereotactic radiotherapy combined with pembrolizumab for oligometastatic renal cell carcinoma. It includes the study design, eligibility criteria, treatment and outcome measures, locations, and completed status.
    Difference
    50%
    Check dated 2026-11-07T16:52:37.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site revision label on the 403 error page changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T16:58:06.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition-related terminology updates above the study page, which continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-24T19:55:05.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-17T20:32:23.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T20:50:39.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    No additions or deletions were reported for this page in the provided data.
    Difference
    0.2%
    Check dated 2026-09-26T20:40:46.000Z thumbnail image

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.